Entecavir and peginterferon alfa‐2a in adults with HB eAg‐positive immune tolerant chronic hepatitis B virus infection-Reference-Cited by-同舟云学术

Entecavir and peginterferon alfa‐2a in adults with HB eAg‐positive immune tolerant chronic hepatitis B virus infection

Published:2018-12-14 Issue: Volume: Page:
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Feld Jordan J.¹,Terrault Norah A.²,Lin Hsing‐Hua S.³,Belle Steven H.³,Chung Raymond T.⁴,Tsai Naoky⁵,Khalili Mandana²,Perrillo Robert⁶,Cooper Stewart L.⁷,Ghany Marc G.⁸,Janssen Harry L.A.¹,Lok Anna S.⁹,

Affiliation:

1. Toronto Centre for Liver Disease University of Toronto

2. University of California San Francisco

3. Graduate School of Public Health University of Pittsburgh Pittsburgh PA

4. Massachusetts General Hospital, Harvard University

5. University of Hawaii

6. Baylor University Medical Center

7. San Francisco Center for Liver Disease California Pacific Medical Centre San FranciscoCA

8. Liver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases National Institutes of Health

9. University of Michigan

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.30417

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of co-signaling receptor modulation in hepatitis B;Cell;2024-07

2. Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis;Reviews in Medical Virology;2024-07

3. Neutralizing antibodies to interferon alfa arising during peginterferon therapy of chronic hepatitis B in children and adults: Results from the HBRN Trials;Hepatology;2024-04-17

4. Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?;Current Hepatology Reports;2024-02-12

5. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion;Gut;2024-01-22